AEterna Zentaris Subsidiary Completes Initial Public Offering

AEterna Zentaris today announced that its subsidiary, Atrium Biotechnologies, has successfully completed its initial public offering and secondary offering of 6,250,000 subordinate voting shares, issued at a price of $12 per share, for total proceeds of $75 million. Atrium Biotechnologies' subordinate voting shares will trade on the Toronto Stock Exchange under the symbol "ATB.sv". The 6,250,000 subordinate voting shares were sold to a syndicate of underwriters co-led by RBC Dominion Securities Inc. and National Bank Financial Inc., and including BMO Nesbitt Burns Inc., CIBC World Markets Inc., GMP Securities Ltd., HSBC Securities (Canada) and Loewen, Ondaatje, McCutcheon.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19605720&full=1)